Click on the links below to read recent Press Releases from Active Motif.
- Active Motif Announces New Report Describing Advancements in Generation and Characterization of Their Recombinant Human COVID-19 Antibodies with Qualities that Make Them Ideal for Use in Diagnostics and Therapeutics
Licensing of patient-derived COVID-19 neutralizing antibodies to Hisun Pharma for co-development and clinical use.
Active Motif launches a portfolio of recombinant COVID-19 antibodies; the first full human antibodies derived from patients infected with the 2019 Coronavirus, now available for research and commercial use.
Active Motif clones, sequences and expresses the first full human antibody derived from patients infected with the 2019 Coronavirus COVID-19.
Active Motif Partners With Benchsci to Increase Discoverability of Epigenetics-related Products
OnRamp's ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamics track plots and advanced collaboration capabilities
VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits
University of Giessen enhances their genome analysis capability with the addition of TimeLogic’s FPGA-based Biocomputing platform
Graz University of Technology enhances their genome analysis capability with the addition of TimeLogic’s FPGA-based Biocomputing platform
Active Motif and Swift Biosciences partner to develop advancements in epigenetics
Forge Therapeutics and Active Motif to Collaborate on Epigenetic Research and Drug Discovery
ChemPartner and Active Motif Form an Epigenetic Biochemical Technology Alliance
Active Motif Acquires SwitchGear Genomics, Inc. Further Expanding Gene Regulation Product Offerings
Active Motif Acquires Genpathway, Inc. Further Expanding Epigenetics Product Offerings
Active Motif Awarded SBIR Grant to Develop Chromatin IP of Clinical Samples
Active Motif Licenses Methylated-CpG Island Recovery Assay (MIRA) from City of Hope